Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) have earned an average recommendation of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $14.86.
A number of brokerages recently commented on TXMD. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. Morgan Stanley began coverage on shares of TherapeuticsMD in a research report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price objective for the company. Deutsche Bank set a $9.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th. Finally, Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th.
In related news, Director Tommy G. Thompson purchased 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The stock was bought at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the transaction, the director now owns 3,555 shares in the company, valued at $22,076.55. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 23.92% of the stock is currently owned by company insiders.
Shares of TherapeuticsMD (NASDAQ:TXMD) traded down $0.01 during trading hours on Tuesday, reaching $6.42. 1,635,300 shares of the company were exchanged, compared to its average volume of 2,810,000. The firm has a market capitalization of $1,390.00, a P/E ratio of -16.46 and a beta of 1.06. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm’s revenue was down 19.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.13) earnings per share. analysts anticipate that TherapeuticsMD will post -0.37 EPS for the current year.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.